Forget Teladoc and Buy This Healthcare Stock Instead

Teladoc and Pfizer have both faced challenges over the past few years. While the latter has a clear path to recovery, the former doesn't seem to.

The Motley Fool • Dec 13, 2025

Health Rounds: Pfizer drug delays progression of advanced breast cancer in trial

Pfizer's Tukysa added to maintenance therapy significantly delayed disease progression in patients with HER2-positive metastatic breast cancer who had responded well to initial treatment, according to results of a late-stage trial.

Reuters • Dec 12, 2025

The Best Turnaround Stock to Invest $1,000 in Right Now

Bristol Myers Squibb's stock is down 35% from its 2022 highs as it faces patent cliffs. Pfizer is down 55% from its 2021 highs as it contends with similar challenges.

The Motley Fool • Dec 12, 2025

Pfizer Is Still Struggling to Replace Its COVID Revenue. Here's What We Could See From the Pharmaceutical Giant in 2026.

Pfizer's coronavirus-related sales have fallen sharply -- and they may decline even further next year. The company is developing some promising products, including a flu vaccine and a weight loss therapy.

The Motley Fool • Dec 12, 2025

Pfizer Declares First-Quarter 2026 Dividend

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 first-quarter 2026 dividend on the company's common stock, payable March 6, 2026, to holders of the Common Stock of record at the close of business on January 23, 2026. The first-quarter 2026 cash dividend will be the 349th consecutive quarterly dividend paid by Pfizer. About Pfizer: Breakthroughs That Change Patients' Lives At Pfizer, we apply science and our global resources to brin.

Business Wire • Dec 12, 2025

Dividend Harvesting Portfolio Week 249: $24,900 Allocated, $2,646.53 In Projected Dividends

The Dividend Harvesting Portfolio remains up 32.60% on invested capital, yielding 8.02%, despite a temporary dip in dividend income from the MSTY reverse split. A dovish Fed rate cut and bullish GDP projections support expectations for a year-end market rally, favoring income-generating, rate-sensitive holdings. Recent capital was allocated to AMLP for high-yield, fee-based energy exposure, and to VZ, citing turnaround potential and robust EBITDA.

Seeking Alpha • Dec 12, 2025

Pfizer to cut hundreds of jobs in Switzerland to reduce costs, Bloomberg News reports

Pfizer will cut hundreds of jobs in Switzerland as part of its multi-year cost reduction program, Bloomberg News reported on Wednesday, citing people familiar with the matter.

Reuters • Dec 10, 2025

PFE Buys Oral GLP-1 Drug From China Biotech to Boost Obesity Presence

Pfizer boosts its obesity ambitions by licensing YP05002, an oral GLP-1 drug now in phase I, aiming to rebuild momentum in weight-loss treatments.

Zacks Investment Research • Dec 10, 2025

Pfizer (PFE) Exceeds Market Returns: Some Facts to Consider

The latest trading day saw Pfizer (PFE) settling at $25.78, representing a +1.78% change from its previous close.

Zacks Investment Research • Dec 10, 2025

TUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced detailed results from the Phase 3 HER2CLIMB-05 trial of the tyrosine kinase inhibitor TUKYSA® (tucatinib) as part of an investigational first-line maintenance treatment combination, following chemotherapy-based induction, in patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC). The primary endpoint analysis showed a 35.9% reduction in the risk of disease progression or death amon.

Business Wire • Dec 10, 2025